Imfinzi Description




Zuellig Pharma
Full Prescribing Info
Each mL contains durvalumab, 50 mg.
Each 120 mg vial of IMFINZI contains 120 mg of durvalumab in 2.4 mL solution.
Each 500 mg vial of IMFINZI contains 500 mg of durvalumab in 10 mL solution.
Durvalumab is a programmed cell death ligand 1 (PD-L1) blocking antibody. Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that is produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture.
IMFINZI (durvalumab) Injection for intravenous use is a sterile, preservative-free, clear to opalescent, colorless to slightly yellow solution, free from visible particles.
Excipients/Inactive Ingredients: Each mL contains L-histidine (2 mg), L-histidine hydrochloride monohydrate (2.7 mg), α,α-trehalose dihydrate (104 mg), Polysorbate 80 (0.2 mg), and Water for Injection, USP.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in